Thermo Fisher Scientific expands its SARS-CoV-2 testing portfolio in India with a point-of-care testing platform

Thermo Fisher Scientific expands its SARS-CoV-2 testing portfolio in India with a point-of-care testing platform

The Accula System is an innovative platform that will accelerate the availability of reliable and accurate advanced molecular diagnostics at the point of care.

Mumbai (Maharashtra) [India], June 15: Thermo Fisher Scientific today announced the introduction of the new and innovative Accula SARS-CoV-2 Test that delivers gold-standard reverse transcription-polymerase chain reaction (RT-PCR) detection of SARS-CoV-2 in a point-of-care format.

The Accula SARS-CoV-2 Test has received Emergency Use Authorization (EUA) from the United States (U.S.) Food and Drug Administration (FDA) for the detection of SARS-CoV-2 in Clinical Laboratory Improvement Amendments (CLIA)–waived environments.

“Since the start of the pandemic, Thermo Fisher has acted quickly to provide support to the scientists and healthcare professionals at the frontlines of combating COVID-19,” said Amit Chopra, Managing Director, India, and South Asia, Thermo Fisher Scientific. “Thermo Fisher’s new testing platform combines the accuracy of RT-PCR with the simplicity, convenience, and procedural familiarity of traditional rapid immunoassays. The Accula SARS-CoV-2 Test is a natural extension to our existing offerings and will significantly help to meet the continuing demands for rapid and reliable COVID-19 testing in India.”

RT-PCR testing is streamlined from start to finish using a fully integrated, single-use microfluidic test cassette and the reusable, palm-sized Accula Dock. The test uses nasal swab samples and provides reliable, qualitative results in approximately 30 minutes. The Accula SARS-CoV-2 Test is enabled by proprietary PCR technology that allows for reduced absolute temperatures and reduced temperature differentials—resulting in rapid exponential amplification while reducing overall thermocycling times.

“The rapid Accula point-of-care test will open new avenues of personal and public testing without compromising on accuracy,” added Amit. “The introduction of the test in India is a demonstration of the impact our solutions have on human health during the pandemic, and far beyond.”

In January 2021, Thermo Fisher acquired Mesa Biotech Inc., which developed the Accula SARS-CoV-2 Test to provide accurate and faster results at the point of care.

For more information, please visit www.thermofisher.com

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $30 billion. Our Mission is to enable our customers to make the world healthier, cleaner, and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies, or increasing productivity in their laboratories, we are here to support them. Our global team of more than 80,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience, and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, and Patheon.

6 thoughts on “Thermo Fisher Scientific expands its SARS-CoV-2 testing portfolio in India with a point-of-care testing platform

  1. I discovered your blog site on google and check a few of your early posts. Continue to keep up the very good operate. I just additional up your RSS feed to my MSN News Reader. Seeking forward to reading more from you later on!…

  2. You could definitely see your enthusiasm in the work you write. The world hopes for even more passionate writers like you who aren’t afraid to say how they believe. Always go after your heart.

  3. Having read this I thought it was very informative. I appreciate you taking the time and effort to put this article together. I once again find myself spending way to much time both reading and commenting. But so what, it was still worth it!

Leave a Reply

Your email address will not be published.